The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Treatment in Patients with Early-Stage Hodgkin's Lymphoma

국소형 호지킨 림프종의 치료

  • Lee, Sung-Eun (Department of Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine) ;
  • Cho, Seok-Goo (Department of Hematology, Seoul St. Mary’s Hospital, The Catholic University of Korea College of Medicine)
  • 이성은 (가톨릭대학교 의과대학 서울성모병원 혈액내과) ;
  • 조석구 (가톨릭대학교 의과대학 서울성모병원 혈액내과)
  • Published : 2011.11.01
⟨ Previous Next ⟩

Abstract

As there has been much progress in radiation therapy, and effective chemotherapy were introduced, the survival outcome of patients with Hodgkin's lymphoma has been significantly improved. Particularly, more than 90% of the patients with early-stage Hodgkin's lymphoma are expected to survive for at least 5 years. This very high survival rate and increasing recognition of the long-term toxicity of treatment including second malignancies led to current studies designed to reduce or eliminate the radiotherapy and minimize the number of chemotherapy cycles. However, because patients with early-stage Hodgkin's lymphoma are not homogeneous group recognition of risk factors in identification of unfavorable Hodgkin's lymphoma is essential for successful therapeutic strategy. Therefore, we will review risk assessment strategies with reference to publications and discuss current standard therapy to maximize therapeutic outcomes and to minimize late, potentially fatal toxicity in early-stage Hodgkin's lymphoma.

Keywords

References

  1. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971;31:1860-1861.
  2. Specht L, Gray RG, Clarke MJ, Peto R. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients: International Hodgkin's Disease Collaborative Group. J Clin Oncol 1998;16:830-843.
  3. Ahn YO, Shin MH. Cancer survival in Seoul, Republic of Korea, 1993-1997. IARC Sci Publ 2011;(162):171-178.
  4. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634-4642. https://doi.org/10.1200/JCO.2005.09.085
  5. Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006;24:3128-3135. https://doi.org/10.1200/JCO.2005.05.2746
  6. Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357:1916-1927. https://doi.org/10.1056/NEJMoa064601
  7. Advani RH, Hoppe RT, Baer DM, Mason J, Rosenberg SA, Horning SJ. Efficacy of abbreviated Stanford V chemotherapy and involved field radiotherapy in early stage Hodgkin's disease: mature results of the G4 trial. Blood 2009;114(Suppl 1):1670.
  8. Engert A, Plütschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640-652. https://doi.org/10.1056/NEJMoa1000067
  9. Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2003;21:3601-3608. https://doi.org/10.1200/JCO.2003.03.023
  10. Pavone V, Ricardi U, Luminari S, et al. ABVD plus radiotherapy versus EVE plus radiotherapy in unfavorable stage IA and IIA Hodgkin's lymphoma: results from an Intergruppo Italiano Linfomi randomized study. Ann Oncol 2008;19:763-768.
  11. Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010;28:4199-4206. https://doi.org/10.1200/JCO.2010.29.8018
  12. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006;17:1749-1760. https://doi.org/10.1093/annonc/mdl302
  13. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005;97:1428-1437. https://doi.org/10.1093/jnci/dji290
  14. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-192. https://doi.org/10.1093/jnci/94.3.182
  15. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003; 95:971-980. https://doi.org/10.1093/jnci/95.13.971
  16. Swerdlow AJ, Schoemaker MJ, Allerton R, et al. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001;19:1610-1618.
  17. Blayney DW, Longo DL, Young RC, et al. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease. N Engl J Med 1987;316: 710-714. https://doi.org/10.1056/NEJM198703193161203
  18. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-1886. https://doi.org/10.1182/blood-2006-07-034405
  19. Engert A, Franklin J, Eich HT, et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007;25:3495-3502. https://doi.org/10.1200/JCO.2006.07.0482